According to filings with the U.S. Securities and Exchange Commission, Aether Therapeutics is raising up to $6,580,866.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, John Harris played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Aether Therapeutics
Aether Therapeutics is an emerging biopharmaceutical company focused on curing diseases associated with the opioid epidemic and finding better therapies for pain. The Aether team combines decades of successful drug development experience focused on curing diseases not simply treating symptoms. Our initial application focuses on the cure and prevention of Neonatal Abstinence Syndrome (NAS) in mothers abusing opioids. Our second application targets withdrawal and weaning for which there is no effective procedure reducing suffering and recidivism. We are a skilled drug development and investor team, with long-standing scientific experiences ranging from molecular biology to pharmacology to addiction specialists. Our collective experience ranges from identifying breakthrough cures to developing novel therapeutics in-house to successful multi-party collaborations with academia and government scientists to advance innovative therapeutics to desperate patients. We search out the best collaborators to help advance our projects no matter where in the world they are performing their science. We are passionately driven to harness innovative science to benefit the patients and caregivers we work with every day.

To learn more about Aether Therapeutics, visit http://www.aethertherapeutics.com/

Contact:
John Harris, Chief Executive Officer
760-783-3085
https://www.linkedin.com/in/john-d-harris-5494156/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.